GENEDRIVE PLC — AGM Information 2018

Dec 7, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8655J

Genedrive PLC

07 December 2018

7 December 2018

genedrive plc ("genedrive" or the "Company")

Result of General Meeting

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that at the General Meeting held earlier today, all the resolutions proposed were duly passed.

The full text of the resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 19 November 2018 which is available on the Company's website http://www.genedriveplc.com/.

Application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 15,217,391 Placing Shares.  It is expected that Admission will become effective at 8.00 a.m. on 10 December 2018.  Following Admission, the Company will have 34,000,506 Ordinary Shares in issue. No shares have been issued under the Broker Option.

Unless otherwise defined, terms in this announcement shall have the same meanings as those defined in the shareholder circular.

-  Ends -

For further details please contact:

genedrive plc David Budd: CEO Matthew Fowler: CFO		+44 (0)161 989 0245
Peel Hunt LLP James Steel Oliver Jackson		+44 (0)207 418 8900
Stanford Capital Partners Limited Patrick Claridge		+44 (0)203 815 8880
John Howes
Consilium Strategic Communications Chris Gardner Matthew Neal Laura Thornton		+44 (0) 203 709 5700 genedrive@consilium-comms.com

Notes to Editors

About genedrive

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® HCV-ID test has received CE-IVD Certification and has been launched in Africa and Asia Pacific. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive® platform in the EMEA and SE Asia (ex-India), and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive® HCV-ID Kit and Genedrive® platform in India. Further details can be found at: www.genedriveplc.com and www.genedrive.com. The Company also has tests in development for tuberculosis (mTB) and Antibiotic Induced Hearing Loss (AIHL).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ROMBSBDDRUGBGIR